IDIOPATHIC INFLAMMATORY MYOPATHIES
Clinical trials for IDIOPATHIC INFLAMMATORY MYOPATHIES explained in plain language.
Never miss a new study
Get alerted when new IDIOPATHIC INFLAMMATORY MYOPATHIES trials appear
Sign up with your email to follow new studies for IDIOPATHIC INFLAMMATORY MYOPATHIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy takes on hard-to-treat muscle disease
Disease control OngoingThis study tests a new treatment called rapcabtagene autoleucel for people with severe idiopathic inflammatory myopathies (muscle inflammation) that hasn't improved with standard therapies. About 21 adults will receive either this cell therapy or a comparator. The main goal is to…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug aims to tame muscle inflammation in myositis
Disease control OngoingThis phase 2 trial tests whether nipocalimab, given intravenously, can improve symptoms of active idiopathic inflammatory myopathies (myositis) better than a placebo. About 36 adults with myositis will receive either nipocalimab or a placebo, along with standard steroid treatment…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Engineered immune cells take on lupus and scleroderma in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES
Phase: PHASE1 • Sponsor: Adicet Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Immune system overhaul: could CAR T-Cells tame autoimmune disease?
Disease control OngoingThis early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could CAR-T cells tame autoimmune diseases? early trial begins
Disease control TerminatedThis early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on lupus and scleroderma in first human test
Disease control OngoingThis early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES
Phase: PHASE1 • Sponsor: Century Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
New tool could predict who will suffer from steroid side effects
Knowledge-focused OngoingThis study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…
Matched conditions: IDIOPATHIC INFLAMMATORY MYOPATHIES
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC